Early initiation of immunotherapy is the most reliable predictor of a positive clinical outcome.
This report focuses on the study titled which was published in the journal Medicine in 2020 under the reference e19601 . Miras-Amanat-E19601:04:57 Min
In severe cases, such as NMDAR (N-methyl-D-aspartate receptor) encephalitis, mortality ranges from approximately 2.9% to 9.5% . Early initiation of immunotherapy is the most reliable